Genetics and quaternary prevention. The example of haemochromatosis;Genética y prevención cuaternaria. El ejemplo de la hemocromatosis

Atencion Primaria

Volumn 32, Issue 3, 2003, Pages 158-162

  Gérvas, Juan ^a,b   Perez Fernandez M ^b  

^a WONCA   (Spain)

^b Equipo CESCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURAL ANTHROPOLOGY; GENETICS; HEMOCHROMATOSIS; PROPHYLAXIS; REVIEW; HUMAN;

HEMOCHROMATOSIS; HUMANS;

EID: 0344823826     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0212-6567(03)79238-5     Document Type: Article

References (20)

1. Reventlow S, Hvas AC, Tulinius C. «In really great danger ... ». The concept of risk in general practice. Scand J Prim Health Care 2001; 19:71-5.
2. Holtzman MA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med 2000; 343:141-4.
3. Pérez Fernández M, Gérvas J. Encarnizamiento diagnóstico y terapéutico con las mujeres. SEMERGEN 1999;25:239-48.
4. Pérez Fernández M, Gérvas J. El efecto cascada: implicaciones clinicas, epidemiológicas y éticas. Med Clin (Barc) 2002;118:65-7.
5. Gérvas J, Pérez Fernández M. Las hiperlipemias y la prevención primaria de la cardiopatía isquémica. Med Clin (Barc) 1997;109: 549-52.
6. Gérvas J. Screening for serious illness. Limits to the power of medicine. Eur J Gen Pract 2002;8:47-9.
7. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
8. Pastor A. Un hito histórico de la humanidad. El Mundo 2003;4882:24.
9. Smith KC. Genetic disease, genetic testing and the clinician. JAMA 2001;285:91.
10. Melzer D, Zimmern R. Genetics and medicalisation. BMJ 2002;324:863-4.
11. Beutler, E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
12. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Gen Med 2002;4:45-61.
13. Haddow JE, Bradley LA. Hereditary haemocrhomatosis: to screen or not to screen. BMJ 1999;319:531-2.
14. Voelker R. Hemochromatosis patients are untapped source of blood as war, shortages lomos. JAMA 2003;289:1364-6.
15. Willis G, Jennigs BA, Fellows TW, Wimperis JZ. A high prevalence of HAL-H 845A mutations in hemochromatosis patients and the normal population in Eastern England. Blood Cells Mol Dis 1977;23:288-91.
16. Merryweather AT, Worwood M, Parkinson L, Mattock C, Pointon JJ, Shearman JD, et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-73.
17. McCune CA, Al-jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adults HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002;111:538-43.
18. Willis G, Wimperis JZ, Smith KC, Fellows TW, Jennings BA. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999;354:221-2.
19. Ibarra J. Genética y atención primaria. Implicaciones. Aten Primaria 2002;30:507-9.
20. Bentzen N, editor. WONCA dictionary of general/family practice [in press]. Copenhagen: Maanedskift Lager, 2003.